Navigation Links
VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Merck's Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
Date:11/17/2010

NEW YORK, Nov. 17, 2010 /PRNewswire/ -- See video from Merck and Co., Inc at:

http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=e64f9345-a404-4b7d-8323-6aa1e1650bc9&alertid=95ea2637-0ea8-4ec1-a5a8-f8083ece9012&bhcp=1#    

Researchers today presented results from the Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study with Merck's investigational CETP inhibitor, anacetrapib. In the trial of 1,623 patients with coronary heart disease (CHD) or CHD risk equivalents, anacetrapib showed no significant differences from placebo in the primary safety measures studied. There were no significant differences in mean changes in blood pressure between the anacetrapib and placebo treatment groups, nor were there any significant differences in serum electrolytes or aldosterone levels. During the 76-week treatment phase, the pre-specified adjudicated cardiovascular endpoint (defined as cardiovascular death, myocardial infarction, unstable angina or stroke) occurred in 16 anacetrapib-treated patients (2.0 percent) compared with 21 placebo-treated patients (2.6 percent) (p=0.40). At 24 weeks, anacetrapib decreased LDL-C by 40 percent (from 81 to 45 mg/dl vs. 82 to 77 mg/dl for placebo, p<0.001) and increased HDL-C by 138 percent (from 40 to 101 mg/dl vs. 40 to 46 mg/dl for placebo, p<0.001) in patients already treated with a statin and at guideline-recommended LDL-C goal. The DEFINE data were presented today at the American Heart Association Scientific Sessions and published concurrently online in the New England Journal of Medicine. Available content includes soundbites and b-roll.

About thenewsmarket.com

thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia con
'/>"/>

SOURCE thenewsmarket.com
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. VIDEO from International Osteoporosis Foundation available on thenewsmarket.com: IOF Focuses on WHO Fracture Risk Assessment Tool for International Discussions
2. Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells
3. VIDEO From thenewsmarket.com and Lundbeck: Lundbeck Continues Strong Growth in Third Quarter
4. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
5. VIDEO from thenewsmarket.com and Roche Pharmaceuticals: MabThera Approved in Europe for First Line Maintenance Treatment of Follicular Lymphoma, a Common Type of Blood Cancer
6. VIDEO From thenewsmarket.com and AstraZeneca: AstraZeneca Announces Third Quarter and Nine Months Results 2010
7. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
8. Generex Reschedules Live Video Webcast
9. Aircraft Medical Launches Worlds First Low Cost Video Laryngoscope
10. New Manhattan Research Report Explores the Growing Consumer Demand for Online Health Video and How Pharma Marketers Can Leverage this Format
11. New Study: Physician Adoption of Live Video Detailing Has Doubled Since 2008, But Will Likely Plateau Until 2012 as Pharma Optimizes Targeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, the ... to announce that the Malcolm Campbell Memorial Prize ... (Vice President of Chemistry), Fiona Marshall (Chief Scientific ... Officer and co-founder) for the seminal contributions to GPCR drug ...
(Date:1/22/2015)... MINNEAPOLIS, Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ended December 31, 2014.  Global revenue for the ... $4.4 million, a new quarterly revenue record, as compared ...
(Date:1/22/2015)...  Bio-Techne Corporation (NASDAQ: TECH ) announced today ... the new Simple Plex platform through its Proteins Platform ... re-branding of the previously acquired CyPlex instrument platform from ... transformative immunoassay technology which integrates an innovatively designed microfluidic ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... In work suggesting a new approach to treating polycystic kidney ... Children,s Hospital Boston were able to block the formation of ... model. Their findings, using a compound that inhibits a receptor ... online edition of the Journal of Clinical Investigation . ...
... PDII ) today announced that Nancy Lurker, the company,s chief ... Sciences Conference at 10:30 am ET on September 20, 2010 at ... may be accessed under the "Investor Relations" tab on the company,s ... 90 days. About PDI PDI ...
Cached Medicine Technology:A New Target in Polycystic Kidney Disease 2A New Target in Polycystic Kidney Disease 3
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Four years since the ... – which coincided with the marriage of Avasa & Matthew Love ... ROAD, which is scheduled for release through White Swan Records on ... that there is a sacred path available to all of us ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... Hospital staff nurses who work extended hours, work at night, ... are more likely to experience a drowsy driving episode, according ... the journal SLEEP. , The study, authored by Linda D. ... Mich., focused on data that were collected from 895 full-time ...
... symptoms, experts warn , SATURDAY, Dec. 1 (HealthDay News) -- ... season of sneezing, congestion and other woes for people with ... American Academy of Allergy, Asthma & Immunology (AAAAI). , But ... say. , "Whether it,s feasting on holiday meals, setting up ...
... The Pediatric Daytime Sleepiness Scale (PDSS) is an ... a sleep-related breathing disorder and daytime sleepiness on a ... the December 1 issue of the journal SLEEP. , ... Universitario Austral in Buenos Aires, Argentina, focused on 2,884 ...
... infections more often than men after heart surgery because ... the risks of bad outcomes, according to a study ... Co-authored by researchers from the University of Rochester Medical ... raises another red flag about transfusions, an ancient medical ...
... (Nasdaq: THOR ), a world leader in ... FDA Circulatory System Devices,Advisory Panel has recommended unanimously ... (PreMarket Approval) allowing the use of its,HeartMate II ... The HeartMate II is a continuous flow ...
... for Research, SAN JOSE, Calif., Nov. 30 Famed ... his recovery from,life threatening injuries due to those stunts. It ... has no treatment and no cure. Knievel,was unfortunately one of ... idiopathic pulmonary fibrosis (IPF) this year, the same number as,will ...
Cached Medicine News:Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 2Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 4Health News:'Tis the Season For Allergy, Asthma 2Health News:PDSS reliable in measuring impact of sleep disorders on teens' academic performance 2Health News:Study links blood transfusions to surgery complications in women 2Health News:Study links blood transfusions to surgery complications in women 3Health News:Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation 2Health News:Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation 3Health News:Evel Knievel Lost to Pulmonary Fibrosis; Disease Claims as Many Lives as Breast Cancer Each Year 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: